Absci (NASDAQ:ABSI) Stock Price Up 12.5% – Should You Buy?

Posted by Brian Himes on Sep 19th, 2026

Absci Corporation (NASDAQ:ABSI – Get Free Report)’s stock price rose 12.5% on Thursday . The company traded as high as $9.04 and last traded at $9.0420. 1,316,516 shares traded hands during trading, a decline of 69% from the average daily volume of 4,274,699 shares. The stock had previously closed at $8.04.

Analyst Ratings Changes

ABSI has been the topic of a number of research reports. BTIG Research set a $15.00 price target on shares of Absci and gave the company a “buy” rating in a report on Tuesday, September 8th. Guggenheim increased their price objective on shares of Absci from $10.00 to $15.00 and gave the company a “buy” rating in a report on Monday, June 15th. Wall Street Zen upgraded Absci from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Truist Financial lifted their target price on Absci from $11.00 to $17.00 and gave the stock a “buy” rating in a report on Thursday, July 2nd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $11.00 target price on shares of Absci in a research report on Wednesday, August 12th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $13.71.

View Our Latest Analysis on Absci

Absci Price Performance

The firm’s 50-day moving average is $8.71 and its two-hundred day moving average is $6.57. The company has a market cap of $1.66 billion, a P/E ratio of -12.06 and a beta of 2.42.

Absci (NASDAQ:ABSI – Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). Absci had a negative net margin of 7,756.38% and a negative return on equity of 61.71%. The business had revenue of $0.32 million for the quarter, compared to analysts’ expectations of $0.92 million. As a group, sell-side analysts expect that Absci Corporation will post -0.74 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. WINTON GROUP Ltd bought a new stake in shares of Absci in the 2nd quarter valued at approximately $445,000. Engineers Gate Manager LP bought a new position in shares of Absci during the 2nd quarter valued at approximately $305,000. Integrated Wealth Concepts LLC bought a new position in shares of Absci during the 2nd quarter valued at approximately $53,000. Corient Private Wealth LP purchased a new stake in Absci during the 2nd quarter valued at $270,000. Finally, AXQ Capital LP raised its holdings in Absci by 10.5% during the 2nd quarter. AXQ Capital LP now owns 36,000 shares of the company’s stock valued at $417,000 after buying an additional 3,435 shares during the period. Hedge funds and other institutional investors own 52.05% of the company’s stock.

About Absci

(Get Free Report)

Absci Corporation is a biotechnology company that uses artificial intelligence and integrated laboratory technologies to discover and develop new biologic medicines. Its platform combines generative artificial intelligence with biological data and wet-lab experimentation to design therapeutic proteins and antibodies, with the goal of improving the speed and efficiency of drug development.

The company’s capabilities include target discovery, protein design, antibody generation, and experimental validation.